Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil

Vaccine

Volumn 33, Issue S1, 2015, Pages A135-A142

  Novaes, Hillegonda Maria Dutilh ^a   de Soárez, Patrícia Coelho ^a   Silva, Gulnar Azevedo ^b   Ayres, Andreia ^b   Itria, Alexander ^c   Rama, Cristina Helena ^d   Sartori, Ana Marli Christovam ^a   Clark, Andrew D ^e   Resch, Stephen ^f  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS   (Brazil)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Cost benefit analysis; HPV vaccines; Papillomavirus vaccines; Uterine cancer; Uterine cervical neoplasms

Indexed keywords

WART VIRUS VACCINE;

ADL DISABILITY; ARTICLE; BRAZIL; CANCER MORTALITY; CANCER REGISTRY; CHILD; CHILD CARE; COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; VACCINATION; VIRUS LOAD; WART VIRUS; ADOLESCENT; ADULT; AGED; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE POLICY; IMMUNOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICAL MODEL; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84928601306     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.12.031     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Summary report 2011.
2. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30(Suppl. 5):F139-F148.
3. (CDC) CfDCaP Progress toward implementation of human papillomavirus vaccination - the Americas, 2006-2010. MMWR Morb Mortal Wkly Rep 2011, 60:1382-1384.
4. Ministério da Saúde, Secretaria de Vigilância em Saúde, Secretaria de Ciência Tecnologia e Insumos Estratégicos, Secretaria de Atenção à Saúde, Instituto nacional de Câncer. Parecer Técnico Conjunto N.01/2011/SVS/SCTIE/SAS/INCA-MS 2011, Ministério da Saúde, Brasília.
5. Novaes H.M.D., Azevedo e Silva G., Ayres A.R., Itria A., Rama C., Sartori A.M.C., et al. Avaliação tecnológica de vacinas para a prevenção de infecção por papilomavírus humano (HPV): estudo de custo-efetividade da incorporação de vacina contra HPV no Programa Nacional de Imunizações/PNI do Brasil. Relatório técnico-científico. Departamento de Medicina Preventiva da Faculdade de Medicina da USP 2012, Ministério da Saúde, São Paulo, 154 pp. Available from: file:///C:/Users/Patr%C3%ADcia%20So%C3%A1rez/Downloads/AVE%20HPV%20(3).pdf [accessed 11.12.14].
6. Toscano C.M., Jauregui B., Janusz C.B., Sinha A., Clark A.D., Sanderson C., et al. Establishing a regional network of academic centers to support decision making for new vaccine introduction in Latin America and the Caribbean: the ProVac experience. Vaccine 2013, 31(Suppl. 3):C12-C18.
7. Instituto Nacional do Câncer - INCA Diretrizes brasileiras para o rastreamento do colo do útero 2011, Ministério da Saúde, Rio de Janeiro, Available from: http://www.mg.vivamulher.com.br/downloads/diretrizes_rastreamento_cancer_colo_utero.pdf [accessed 11.12.14].
8. World Bank Data official exchange rate (LCU per US$, period average) 2008, Available from: http://data.worldbank.org/indicator/PA.NUS.FCRF [accessed 11.12.14].
9. Brasil.Ministério da Saúde.Secretaria de Ciência, Tecnologia e Insumos Estratégicos.Departamento de Ciência e Tecnologia Diretrizes Metodológicas: estudos de avaliação econÔmica de tecnologias em saúde 2009, Ministério da Saúde, Brasília, 152 pp. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/avaliacao_economica_tecnologias_saude_2009.pdf [accessed 11.12.14].
10. Silva G.A., Gamarra C.J., Girianelli V.R., Valente J.G. Cancer mortality trends in Brazilian state capitals and other municipalities between 1980 and 2006. Rev Saude Publica 2011, 45:1009-1018.
11. Gamarra C.J., Valente J.G., Silva G.A. Correction for reported cervical cancer mortality data in Brazil, 1996-2005. Rev Saude Publica 2010, 44:629-638.
12. Ayres A., Silva G., Guimaraes R. Trends in incidence of cancer of the cervix intruder in four Brazilian cities: data from population-based cancer registries, 1990-2004. Cad Saúde Colet 2013, 21:289-295.
13. Fundação Oncocentro de São Paulo - Secretaria de Estado de São Paulo Sobrevida de pacientes com câncer no Estado de São Paulo: seis anos de seguimento pelo Registro Hospitalar de Câncer 2009, 97-104. Cadernos FOSP.
14. WHO Global burden of disease 2004 update: disability weights for diseases and conditions 2004, 9. World Health Organization.
15. WHO WHO methods and data sources for global burden of disease estimates 2000-2011 2013, 86. WHO, Geneva, Available from: http://www.who.int/healthinfo/statistics/GlobalDALYmethods_2000_2011.pdf [accessed 11.12.14].
16. Instituto Brasileiro de Geografia Pesquisa Nacional de Amostra por Domicílios 2008, IBGE, Rio de Janeiro, Available from: http://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/pnad2008/ [accessed 11.12.14].
17. Brasil.Ministério da Saúde Instituto Nacional de Câncer - INCA Plano de ação para redução da incidência e mortalidade por câncer de colo de útero: sumário executivo 2010, Instituto Nacional de Câncer, Rio de Janeiro.
18. SIAB - Sistema de Informação da Atenção Básica 2014, Available from: http://www2.datasus.gov.br/SIAB/index.php [accessed 11.12.14].
19. SIA - Sistema de Informações Ambulatoriais 2014, Available from: http://sia.datasus.gov.br/principal/index.php [accessed 11.12.14].
20. SISCOLO/SISMAMA - Sistema de Informação do câncer do colo do útero e Sistema de Informação do câncer de mama 2013, Available from: http://http://w3.datasus.gov.br/siscam/index.php [accessed 11.12.14].
21. SIH/SUS Sistema de Informações Hospitalares do SUS 2013, Available from: http://www2.datasus.gov.br/SIHD/institucional [accessed 11.12.14].
22. SIGTAP - Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e Órteses, Próteses e Materiais Especiais do SUS 2013, Available from: http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp [accessed 11.12.14].
23. Sistema do Banco de Preços em Saúde 2013, Available from: http://aplicacao.saude.gov.br/bps/login.jsf [accessed 11.12.14].
24. Murta E., Reis J., Abrão L., Miziara J. Histerectomias: estudo retrospectivo de 554 casos. Rev Col Bras Cir 2000, 27:307-311.
25. PNAD - Pesquisa Nacional por Amostra de Domicílios 2008, Instituto Brasileiro de Geografia e Estatística - IBGE, Rio de Janeiro.
26. PNAD - Pesquisa Nacional por Amostra de Domicílios 2006, 125. Instituto Brasileiro de Geografia e Estatística - IBGE, Rio de Janeiro.
27. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'shea M.K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25:6257-6270.
28. Commission on Macroeconomics and Health Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health 2001, World Health Organization, Geneva.
29. Fesenfeld M., Hutubessy R., Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine 2013, 31:3786-3804.
30. Colantonio L., Gómez J.A., Demarteau N., Standaert B., Pichón-Rivière A., Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009, 27:5519-5529.
31. Vanni T., Mendes Luz P., Foss A., Mesa-Frias M., Legood R. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine 2012, 30:4866-4871.
32. Demarteau N., Breuer T., Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics 2012, 30:337-353.
33. Jit M., Levin C., Brisson M., Levin A., Resch S., Berkhof J., et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. BMC Med 2013, 11:23.
34. Vaccarella S., Lortet-Tieulent J., Plummer M., Franceschi S., Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013, 49:3262-3273.
35. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309:1793-1802.
36. Lazcano-Ponce E., Stanley M., Muñoz N., Torres L., Cruz-Valdez A., Salmerón J., et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014, 32:725-732.
37. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
38. Franco E.L., de Sanjosé S., Broker T.R., Stanley M.A., Chevarie-Davis M., Isidean S.D., et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine 2012, 30(Suppl. 5):F175-F182.